I still like their product, EECP.
I no longer own any shares of VASO because, from a technical standpoint, these are overvalued at $2 (in view of the number of shares out there, and the lack of profit).
Somebody must know, however, where the result of the 120 patients trial stand, because the deadline for abstract submission for the American Heart Association is, I believe early this coming week... so... Vasomedical will know, probably, because the 4+ centers will have written up their results... and I am convinced that somebody must have seen it by now... I wish we did not have to wait until November, when this abstract will be presented (if accepted)... If I have any new information on EECP, I will post it here.
Gaston |
